A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

NCT04138875 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding

Conditions

PTLD
Lymphoid Tumor
Hematopoietic/Lymphoid Cancer
Plasmacytic Hyperplasia PTLD
Infectious Mononucleosis
Florid Follicular Hyperplasia PTLD
Polymorphic PTLD
Monomorphic PTLD
Classical Hodgkin Lymphoma Type PTLD

Interventions

DRUG: Rituximab
DRUG: Brentuximab Vedotin
DRUG: Bendamustine

Sponsor

Yale University